Kirkland & Ellis LLP is a multinational corporate law firm headquartered in Chicago, Illinois, founded in 1909. One of the world's largest and most profitable law firms, it employs over 3,800 attorneys across 23 offices in the United States, Europe, the Middle East, and Asia.
The firm specializes in private equity, mergers and acquisitions, complex corporate transactions, litigation, restructurings, intellectual property, and government investigations. Kirkland & Ellis is renowned for advising on high-profile deals, including major acquisitions in technology, data centers, and pharmaceuticals.
All-stock merger creates an integrated North American chemicals platform with vertical chlorine/caustic integration, ~$12.5B pro forma revenue and $400M+ identified synergies.
Lead program in Phase 1; POC data due late 2026. Designed to deliver deeper, more durable responses than current Type I JAK2 therapies. Deal may pay up to $2.3B, subject to closing.
Buyer will acquire a clinical-stage in vivo CAR-T developer for up to $7B (incl. $3.25B upfront). Lead KLN-1010 (lentiviral anti-BCMA) showed promising Phase 1 ASH data; close expected H2 2026.
$38/ADS cash + up to $9 CVR (max $47/sh); upfront equity ~$6.3B (CVR ~$1.5B). Lead OX2R agonist cleminorexton showed positive Phase 2a for narcolepsy and idiopathic hypersomnia. Close expected Q3
